Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

Lukoil in first half of 2025 reduced oil production by 3.9%

9/26/25 LKOH

Bank Saint Petersburg to repay 460 thousand ordinary shares

9/26/25 BSPB

Shareholders of Bank St. Petersburg approved

9/26/25 BSPB

Shareholders of Tatneft approved dividends

9/26/25 TATN

Shareholders of NOVATEK approved dividends

9/26/25 NVTK

Ozon has completed its re-registration in Russia

9/26/25 OZON

RussNeft in first half of 2025 increased oil production by 1.74%

9/26/25 RNFT

Astra and UZTELECOM have agreed to cooperate

9/26/25 ASTR

Authorities are looking for ways to attract SMEs to the MAX messenger

9/26/25 VKCO

Rusagro paid ₽31 billion for 77.5% of Agro-Belogorye

9/26/25 RAGR